Timothy J. Scannell currently serves as an executive advisor and will be supporting senior Stryker leaders in this role until April 1, 2023, when he will fully retire from Stryker. Tim retired from his role as president and chief operating officer on September 30, 2021.
Tim is a thirty-one-year Stryker veteran. He joined Stryker in 1990 with the Endoscopy division, where he served in sales and marketing leadership roles for over a decade. In 2001, Tim was promoted to the role of vice president and general manager of our Biotech division. In 2003, he was named vice president and general manager of our Spine division and was later promoted to division president.
In 2009, Tim was appointed to the position of group president and initially was responsible for the Spine and Endoscopy divisions. After one year, the role expanded to include all of Stryker’s MedSurg and Neurotechnology businesses, with each of the group’s divisional leaders reporting to him. He served in this role until his promotion to president and chief operating officer in 2018, where he was responsible for all of Stryker’s operating businesses and regions.
Tim serves as a director and non-executive chairman on the board of directors for Insulet Corporation, whose OmniPod® Insulin Management System helps to improve the lives of people with diabetes. He is also a director on the boards of Novocure, a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Collagen Matrix, which develops and manufactures collagen based products to advance bone and tissue repair and regeneration.
Tim holds bachelor’s and master’s degrees in business administration from the University of Notre Dame.
What is Timothy J. Scannell's net worth?
The estimated net worth of Timothy J. Scannell is at least $13.75 million as of June 10th, 2024. Mr. Scannell owns 35,586 shares of Stryker stock worth more than $13,753,633 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Scannell may own. Learn More about Timothy J. Scannell's net worth.
How do I contact Timothy J. Scannell?
Has Timothy J. Scannell been buying or selling shares of Stryker?
Timothy J. Scannell has not been actively trading shares of Stryker during the last ninety days. Most recently, Timothy J. Scannell sold 5,000 shares of the business's stock in a transaction on Monday, November 23rd. The shares were sold at an average price of $232.61, for a transaction totalling $1,163,050.00. Learn More on Timothy J. Scannell's trading history.
Who are Stryker's active insiders?
Stryker's insider roster includes Yin Becker (VP), William Berry, Jr. (VP), Glenn Boehnlein (CFO), Srikant Datar (Director), Roch Doliveux (Director), M. Fink (VP), Robert Fletcher (VP), Allan Golston (Director), Kevin Lobo (CEO), Katherine Owen (VP), James Pierce (Insider), Bijoy Sagar (VP), Timothy Scannell (COO), and Ronda Stryker (Director). Learn More on Stryker's active insiders.
Are insiders buying or selling shares of Stryker?
In the last year, insiders at the medical technology company sold shares 10 times. They sold a total of 490,063 shares worth more than $165,955,919.20. The most recent insider tranaction occured on November, 7th when CEO Kevin Lobo sold 57,313 shares worth more than $21,131,303.10. Insiders at Stryker own 5.9% of the company.
Learn More about insider trades at Stryker. Information on this page was last updated on 11/7/2024.
